Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Johnson

Showing results (111-120 of 137) with videos related to

Pageof 14
Sort By:
Alzheimer'S & Dementia (Amsterdam, Netherlands)|October 8, 2021
Unsupervised mobile cognitive testing for use in preclinical Alzheimer's diseaseKathryn V Papp, Aubryn Samaroo, Hsiang-Chin Chou, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 17, 2024
Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trialDoris Patricia Molina-Henry, Rema Raman, Andy Liu, et al.
Journal of Neurotrauma|June 7, 2023
Tau Positron Emission Tomography and Neurocognitive Function Among Former Professional American-Style Football PlayersMaeva Dhaynaut, Rachel Grashow, Marc D Normandin, et al.
Alzheimer'S Research & Therapy|March 20, 2025
Tau-PET pathology in the subregions of the amygdala and its associations with cognitive performance and neuropsychiatric symptoms in autosomal dominant Alzheimer's diseaseCatarina Tristão-Pereira, Stephanie Langella, Justin S Sanchez, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 26, 2011
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's diseaseClifford R Jack, Frederik Barkhof, Matt A Bernstein, et al.
BMJ Open|March 7, 2023
Geographically skewed recruitment and COVID-19 seroprevalence estimates: a cross-sectional serosurveillance study and mathematical modelling analysisTyler Brown, Pablo Martinez de Salazar Munoz, Abhishek Bhatia, et al.
Science Advances|March 5, 2025
Associations between hormone therapy use and tau accumulation in brain regions vulnerable to Alzheimer's diseaseGillian T Coughlan, Zoe Rubinstein, Hannah Klinger, et al.
Medrxiv : the Preprint Server for Health Sciences|February 10, 2021
Recruitment location influences bias and uncertainty in SARS-CoV-2 seroprevalence estimatesTyler S Brown, Pablo Martinez de Salazar Munoz, Abhishek Bhatia, et al.
JAMA Neurology|June 4, 2019
Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal StudyBernard J Hanseeuw, Rebecca A Betensky, Heidi I L Jacobs, et al.
Nature Medicine|November 10, 2022
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive declineRik Ossenkoppele, Alexa Pichet Binette, Colin Groot, et al.
Pageof 14

Showing results (111-120 of 137) with videos related to

Sort By:
Pageof 14
Alzheimer'S & Dementia (Amsterdam, Netherlands)|October 8, 2021
Unsupervised mobile cognitive testing for use in preclinical Alzheimer's diseaseKathryn V Papp, Aubryn Samaroo, Hsiang-Chin Chou, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 17, 2024
Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trialDoris Patricia Molina-Henry, Rema Raman, Andy Liu, et al.
Journal of Neurotrauma|June 7, 2023
Tau Positron Emission Tomography and Neurocognitive Function Among Former Professional American-Style Football PlayersMaeva Dhaynaut, Rachel Grashow, Marc D Normandin, et al.
Alzheimer'S Research & Therapy|March 20, 2025
Tau-PET pathology in the subregions of the amygdala and its associations with cognitive performance and neuropsychiatric symptoms in autosomal dominant Alzheimer's diseaseCatarina Tristão-Pereira, Stephanie Langella, Justin S Sanchez, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 26, 2011
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's diseaseClifford R Jack, Frederik Barkhof, Matt A Bernstein, et al.
BMJ Open|March 7, 2023
Geographically skewed recruitment and COVID-19 seroprevalence estimates: a cross-sectional serosurveillance study and mathematical modelling analysisTyler Brown, Pablo Martinez de Salazar Munoz, Abhishek Bhatia, et al.
Science Advances|March 5, 2025
Associations between hormone therapy use and tau accumulation in brain regions vulnerable to Alzheimer's diseaseGillian T Coughlan, Zoe Rubinstein, Hannah Klinger, et al.
Medrxiv : the Preprint Server for Health Sciences|February 10, 2021
Recruitment location influences bias and uncertainty in SARS-CoV-2 seroprevalence estimatesTyler S Brown, Pablo Martinez de Salazar Munoz, Abhishek Bhatia, et al.
JAMA Neurology|June 4, 2019
Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal StudyBernard J Hanseeuw, Rebecca A Betensky, Heidi I L Jacobs, et al.
Nature Medicine|November 10, 2022
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive declineRik Ossenkoppele, Alexa Pichet Binette, Colin Groot, et al.
Pageof 14